Designing Multi-Target Drugs

Content: Preface; Forewords; Simple drugs do not cure complex diseases - the need for multi-targeted drugs; Clinical Need and Rationale for Multi-Target Drugs in Psychiatry; Drug molecules and biology: network and systems aspects; Chemoinformatic approaches to target identification; In vitro Panel Screening - Biological Fingerprinting; Phenotypic and in vivo Screening; Lead Discovery and Drug Repurposing; Target/s identification approaches - experimental biological approaches; Historical strategies for lead generation; In silico Lead Generation Approaches in Multi-Target Drug Discovery; The challenges of multi-target lead optimization; Combination agents versus multi-targeted agents - pros and cons; CASE STUDIES: The Discovery of Lapatinib; Identification and optimization of dual PI3K/mTOR inhibitors; Discovery of HDAC-inhibiting multi-target inhibitors; Targeting protein-protein interactions; dual inhibitors of Bcl-2 and Bcl-xL; Discovery of the anti-psychotic drug, Ziprasidone; The Rational Design of Triple Reuptake Inhibitors for the Treatment of Depression; Discovery of multi-target agents for neurological diseases via ligand design; Designing Drugs with Dual Activity: Novel Dual Angiotensin II and Endothelin Receptor Antagonists; Case study 10: Ethyl Urea Inhibitors of the Bacterial Type II Topoisomerases DNA Gyrase (GyrB) and Topoisomerase IV (ParE); Epilogue; Index